Search filters
Integrity and Transparency for Therapeutic Products – 6 Common Myths

Integrity and Transparency for Therapeutic Products – 6 Common Myths

On 1 January 2020, the new provisions on integrity and transparency and on the passing on of discounts and benefits in the therapeutic products sector entered into force. The former provision on the promise and acceptance of...

Management of Clinical Trials in COVID-19 Times

Management of Clinical Trials in COVID-19 Times

COVID-19 is becoming increasingly widespread in many countries, leading to an overload of hospitals, medical staff and clinical resources. Ongoing or planned clinical trials are threatened by COVID-19 related bottlenecks....

EU Commission calls for postponement of the MDR start date

EU Commission calls for postponement of the MDR start date

The Agreement between Switzerland and the EU on mutual recognition in relation to conformity assessment (MRA) is part of the package of seven Bilateral I Agreements in place between Switzerland and the European Union. The MRA is...

MDR Effective from 26 May 2020 – Medical Device Makers Required to Act

MDR Effective from 26 May 2020 – Medical Device Makers Required to Act

On 26 May 2020, the new Regulation 2017/745 of the European Parliament and of the Council of 5 April 2017 on Medical Devices (Medical Device Regulation, "MDR") will become effective. The MDR replaces the previous legal bases valid...

China Adopts Modern Drug Legislation

China Adopts Modern Drug Legislation

The Chinese healthcare system is currently undergoing significant changes. With the most extensive amendments in the past decade, the Drug Administration Act of the People's Republic of China (DAL) will enter into force on...

Trends in the Swiss Cannabis Regulation

Trends in the Swiss Cannabis Regulation

One of currently fastest growing industries are cannabis companies along the value chain of cannabis, such as e.g. pharmaceutical companies around the different application forms of cannabis. Due to significant regulatory changes all over the world, many growers, manufacturers and pharmaceutical companies are exploring the opportunities of the "new" now slowly legalized commodity cannabis. Whilst pharmaceutical companies see the chances of its medical effects, the commercial industry intends to satisfy the desires of the recreational application of cannabis.

Aktuelles aus der Preissenkungspraxis des BAG

Offene Fragen zum therapeutischen Quervergleich des BAG Im Rahmen der diesjährigen Preisüberprüfungsrunde spricht das BAG derzeit für viele Arzneimittel Preissenkungsverfügungen aus. Bei Arzneimitteln, die in keinem der...

You are currently offline. Some pages or content may fail to load.